- Home
- CHRS vs FRGE Comparison
CHRS vs FRGE Comparison
Compare CHRS & FRGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FRGE
- Stock Information
- Founded
- CHRS 2010
- FRGE 2014
- Country
- CHRS United States
- FRGE United States
- Employees
- CHRS 235
- FRGE N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FRGE Computer Software: Prepackaged Software
- Sector
- CHRS Health Care
- FRGE Technology
- Exchange
- CHRS Nasdaq
- FRGE Nasdaq
- Market Cap
- CHRS 134.4M
- FRGE 176.0M
- IPO Year
- CHRS 2014
- FRGE N/A
- Fundamental
- Price
- CHRS $1.22
- FRGE $0.80
- Analyst Decision
- CHRS Strong Buy
- FRGE Buy
- Analyst Count
- CHRS 4
- FRGE 4
- Target Price
- CHRS $5.38
- FRGE $4.50
- AVG Volume (30 Days)
- CHRS 2.4M
- FRGE 620.4K
- Earning Date
- CHRS 03-12-2025
- FRGE 03-25-2025
- Dividend Yield
- CHRS N/A
- FRGE N/A
- EPS Growth
- CHRS N/A
- FRGE N/A
- EPS
- CHRS N/A
- FRGE N/A
- Revenue
- CHRS $304,340,000.00
- FRGE $79,799,000.00
- Revenue This Year
- CHRS $2.47
- FRGE $19.00
- Revenue Next Year
- CHRS N/A
- FRGE $35.73
- P/E Ratio
- CHRS N/A
- FRGE N/A
- Revenue Growth
- CHRS 44.19
- FRGE 18.08
- 52 Week Low
- CHRS $0.66
- FRGE $0.70
- 52 Week High
- CHRS $2.87
- FRGE $3.56
- Technical
- Relative Strength Index (RSI)
- CHRS 44.03
- FRGE 45.96
- Support Level
- CHRS $1.03
- FRGE $0.72
- Resistance Level
- CHRS $1.23
- FRGE $0.80
- Average True Range (ATR)
- CHRS 0.13
- FRGE 0.06
- MACD
- CHRS -0.02
- FRGE 0.01
- Stochastic Oscillator
- CHRS 38.89
- FRGE 46.27
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The Company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.